Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has reiterated a Speculative Buy rating on Intensity Therapeutics (NASDAQ:INTS) and maintained a $12 price target for the company's stock.
November 14, 2023 | 2:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intensity Therapeutics receives a Speculative Buy rating and a $12 price target from Benchmark analyst Robert Wasserman.
The reiteration of a Speculative Buy rating and the maintenance of a $12 price target by a Benchmark analyst could lead to increased investor confidence and potential upward movement in INTS's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100